Tracers / [68Ga]HTK03189B
[68Ga]HTK03189B
Also written as [Ga-68]Ga-HTK03189B
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- PSMA-targeting Lys-urea-Api pharmacophore ligand (HTK03189)
- Target / mechanism
- PSMA (prostate-specific membrane antigen) targeting via Lys-urea-based pharmacophore PMID 36168623
- Clinical application
- Prostate cancer (PSMA-expressing) PMID 36168623
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | HPLC | — | — | HTK03189 | 36168623 2022 Theranostics |
Need this precursor?We can point you to suppliers for [68Ga]HTK03189B, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36168623. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36168623: 'Since racemic Api was used for the synthesis of HTK03189, two isomers (HTK03189A and HTK03189B) were obtained after HPLC purification'.